PCSK9-Targeted Therapy Market Size to Hit USD 28.71 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on PCSK9-Targeted Therapy Market

5.1. COVID-19 Landscape: PCSK9-Targeted Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global PCSK9-Targeted Therapy Market, By Drug Type / Modality

8.1. PCSK9-Targeted Therapy Market Revenue and Volume, by Drug Type / Modality

8.1.1. Monoclonal Antibodies (mAbs)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. siRNA-based Therapies

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Gene Editing & Other Novel Modalities

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global PCSK9-Targeted Therapy Market, By Indication

9.1. PCSK9-Targeted Therapy Market Revenue and Volume, by Indication

9.1.1. Heterozygous Familial Hypercholesterolemia (HeFH)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Atherosclerotic Cardiovascular Disease (ASCVD)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Homozygous Familial Hypercholesterolemia (HoFH)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Hyperlipidemia (Non-FH)

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global PCSK9-Targeted Therapy Market, By Route of Administration

10.1. PCSK9-Targeted Therapy Market Revenue and Volume, by Route of Administration

10.1.1. Subcutaneous Injection

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Intravenous Injection

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Oral (in pipeline)

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global PCSK9-Targeted Therapy Market, By Distribution Channel

11.1. PCSK9-Targeted Therapy Market Revenue and Volume, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global PCSK9-Targeted Therapy Market, By Patient Type

12.1. PCSK9-Targeted Therapy Market Revenue and Volume, by Patient Type

12.1.1. Primary Prevention (High Risk, No History of ASCVD)

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Secondary Prevention (With History of ASCVD)

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Statin-Intolerant Patients

12.1.3.1. Market Revenue and Volume Forecast

Chapter 13. Global PCSK9-Targeted Therapy Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.1.2. Market Revenue and Volume Forecast, by Indication

13.1.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.5. Market Revenue and Volume Forecast, by Patient Type

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.1.6.2. Market Revenue and Volume Forecast, by Indication

13.1.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.6.5. Market Revenue and Volume Forecast, by Patient Type

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.1.7.2. Market Revenue and Volume Forecast, by Indication

13.1.7.3. Market Revenue and Volume Forecast, by Route of Administration

13.1.7.4. Market Revenue and Volume Forecast, by Distribution Channel

13.1.7.5. Market Revenue and Volume Forecast, by Patient Type

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.2.2. Market Revenue and Volume Forecast, by Indication

13.2.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.5. Market Revenue and Volume Forecast, by Patient Type

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.2.6.2. Market Revenue and Volume Forecast, by Indication

13.2.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.7. Market Revenue and Volume Forecast, by Distribution Channel

13.2.8. Market Revenue and Volume Forecast, by Patient Type

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.2.9.2. Market Revenue and Volume Forecast, by Indication

13.2.9.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.10. Market Revenue and Volume Forecast, by Distribution Channel

13.2.11. Market Revenue and Volume Forecast, by Patient Type

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.2.12.2. Market Revenue and Volume Forecast, by Indication

13.2.12.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.12.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.13. Market Revenue and Volume Forecast, by Patient Type

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.2.14.2. Market Revenue and Volume Forecast, by Indication

13.2.14.3. Market Revenue and Volume Forecast, by Route of Administration

13.2.14.4. Market Revenue and Volume Forecast, by Distribution Channel

13.2.15. Market Revenue and Volume Forecast, by Patient Type

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.3.2. Market Revenue and Volume Forecast, by Indication

13.3.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.5. Market Revenue and Volume Forecast, by Patient Type

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.3.6.2. Market Revenue and Volume Forecast, by Indication

13.3.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.7. Market Revenue and Volume Forecast, by Patient Type

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.3.8.2. Market Revenue and Volume Forecast, by Indication

13.3.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.9. Market Revenue and Volume Forecast, by Patient Type

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.3.10.2. Market Revenue and Volume Forecast, by Indication

13.3.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.10.5. Market Revenue and Volume Forecast, by Patient Type

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.3.11.2. Market Revenue and Volume Forecast, by Indication

13.3.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.3.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.3.11.5. Market Revenue and Volume Forecast, by Patient Type

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.4.2. Market Revenue and Volume Forecast, by Indication

13.4.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.5. Market Revenue and Volume Forecast, by Patient Type

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.4.6.2. Market Revenue and Volume Forecast, by Indication

13.4.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.7. Market Revenue and Volume Forecast, by Patient Type

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.4.8.2. Market Revenue and Volume Forecast, by Indication

13.4.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.9. Market Revenue and Volume Forecast, by Patient Type

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.4.10.2. Market Revenue and Volume Forecast, by Indication

13.4.10.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.10.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.10.5. Market Revenue and Volume Forecast, by Patient Type

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.4.11.2. Market Revenue and Volume Forecast, by Indication

13.4.11.3. Market Revenue and Volume Forecast, by Route of Administration

13.4.11.4. Market Revenue and Volume Forecast, by Distribution Channel

13.4.11.5. Market Revenue and Volume Forecast, by Patient Type

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.5.2. Market Revenue and Volume Forecast, by Indication

13.5.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.5. Market Revenue and Volume Forecast, by Patient Type

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.5.6.2. Market Revenue and Volume Forecast, by Indication

13.5.6.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.7. Market Revenue and Volume Forecast, by Patient Type

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Drug Type / Modality

13.5.8.2. Market Revenue and Volume Forecast, by Indication

13.5.8.3. Market Revenue and Volume Forecast, by Route of Administration

13.5.8.4. Market Revenue and Volume Forecast, by Distribution Channel

13.5.8.5. Market Revenue and Volume Forecast, by Patient Type

Chapter 14. Company Profiles

14.1. Sanofi

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Eli Lilly and Company

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Silence Therapeutics

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Verve Therapeutics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. AstraZeneca plc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Cerenis Therapeutics

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Hansa Biopharma

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Lexicon Pharmaceuticals

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. MeiraGTx Holdings

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Beam Therapeutics

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global PCSK9-targeted therapy market is expected to increase from USD 10.54 billion in 2024 to USD 28.71 billion by 2034.

The PCSK9-targeted therapy market is expected to grow at a compound annual growth rate (CAGR) of around 10.54% from 2025 to 2034.

The major players in the PCSK9-targeted therapy market include Amgen Inc., Sanofi, Regeneron Pharmaceuticals, Inc., Novartis AG, Alnylam Pharmaceuticals, The Medicines Company (acquired by Novartis), Eli Lilly and Company, Arrowhead Pharmaceuticals, Silence Therapeutics, Verve Therapeutics, Ionis Pharmaceuticals, AstraZeneca plc, Pfizer Inc., Roche Holding AG, Cerenis Therapeutics, Hansa Biopharma, Sino Biopharmaceutical Limited , Lexicon Pharmaceuticals, MeiraGTx Holdings, and Beam Therapeutics.

The driving factors of the PCSK9-targeted therapy market are the growing aging population and rising prevalence of cardiovascular disease in aging populations have increased the need for effective cholesterol-reducing therapies, including PCSK9-targeted therapies.

North America region will lead the global PCSK9-targeted therapy market during the forecast period 2025 to 2034.